McMillan LLP demonstrates strength across transactional, intellectual property, litigation, competition, regulatory, and privacy matters. The team advises on a range of transactions, including cross-border acquisitions, plans of arrangements, debt refinancings, and note offerings. On the contentious side, the practice handles product liability class actions, drug price-fixing class actions, and shareholder disputes. Practice head Scott Maidment is noted for his litigation expertise, with a concentration on disputes, including class actions, product liability, and regulatory proceedings.
Legal 500 Editorial commentary

Key clients

  • Future Pak
  • Bright Minds Biosciences
  • SON Medical Innovations
  • JPMorgan Chase Bank
  • Covalon Technologies
  • Truly Green Plastic
  • 900631 Ontario Inc. dba Aurora Compounding Pharmacy
  • Eastern Currents Distributing
  • Samil Pharmaceutical
  • Sylvester.ai
  • Redwood.ai
  • Psyence Biomedical
  • Valeo Pharma
  • Richter
  • BDC Capital
  • Express Scripts Canada
  • Symrise & Spécialités Pet Food

Work highlights

Supported Bright Minds Biosciences in its $175m underwritten public offering of common shares, completed on January 9, 2026, marking the company's largest financing to date and valuing it at over $1bn.
Acted as co-counsel to the Saugeen Ojibway Nation in connection with its C$255m bond-financed investment in a partnership with Bruce Power to produce cancer-fighting medical isotopes.
Acted as lead Canadian counsel to Future Pak in its $254m acquisition of Theratechnologies, a cross-border public company transaction completed by plan of arrangement on September 25, 2025.
Practice head

Scott Maidment

Other key lawyers

Paul Barbeau; Peter Giddens; Samantha Gordon; Lyndsay Wasser; Kristen Pennington